Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial Hypercholesterolemia
NCT07058077Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Primary completion
- Dec 2033
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 19
01
Overview
A Phase 3 trial of enlicitide in heterozygous familial hypercholesterolemia (HeFH), sponsored by Merck & Co.. Started Aug 2025; status: recruiting.
02
Drugs
enlicitide
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT07058077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058077.